Clinical Trial Results:
A double-blind, double dummy, randomized, parallel group, multi-centre Phase III study to evaluate the efficacy and safety of TAK-475 100 mg and TAK-475 100 mg administered in combination with ezetimibe 10 mg versus ezetimibe 10 mg in subjects with primary dyslipidemia.
Summary
|
|
EudraCT number |
2005-002315-25 |
Trial protocol |
GB EE FI LV LT HU DE |
Global completion date |
09 Jan 2007
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
02 Jan 2017
|
First version publication date |
02 Jan 2017
|
Other versions |
|
Summary report(s) |
Summary Results |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.